1 Reason This $900 Stock Could Announce a Split in 2026

Eli Lilly reported fiscal 2025 revenue up 45% YoY to ~$65.2B and EPS up 86% YoY to $24.20, driven by Mounjaro revenue (+99% to ~$23B) and Zepbound (+175% to ~$13.5B). The company is guiding fiscal 2026 revenue of $80B–$83B, expects pricing to subtract low- to mid-teens percentage points while volume growth more than offsets it, and notes GLP-1 penetration remains only mid-single digits in the U.S., implying sizable runway. Lilly has committed >$55B to manufacturing expansion since 2020, is advancing 36 active late-stage (Phase 3) programs, and is preparing to launch oral GLP-1 orforglipron—factors supporting continued market share gains and fueling stock-split speculation for 2026.

Analysis

The market is treating the company as a quasi-monopoly within the GLP-1/metabolic category, but the durable opportunity is less about a single product and more about ecosystem control — manufacturing throughput, payer contracting, and distribution channels. That implies any player that secures disproportionate fill-finish capacity and exclusive supply terms with PBMs will not only scale faster but also raise the bar for new entrants; conversely, overbuild in capex without demand stickiness creates stranded asset risk and margin pressure.

An oral GLP-1 entrant is the true asymmetric catalyst: it can expand total addressable patients by converting needle-averse cohorts and accelerating initiation, but it also changes unit economics (smaller per-patient revenue, higher churn) and forces payers to reprice formularies. Expect the competitive response to bifurcate into (1) aggressive payer rebates and step therapy to control short-term spend and (2) product-line extensions that aim to lock patients into on-label chronic use — both outcomes favor firms with deep payer relationships and integrated manufacturing.

Regulatory and real-world safety readouts are low-probability, high-impact risks that would compress multiples quickly; alternatively, evidence showing durable weight maintenance on therapy would materially improve lifetime value per patient and justify higher valuations. In the near term, investor sentiment and liquidity events (share actions, capital allocation announcements) will drive price moves; over the medium term, adoption curves and payer policy shifts will set earnings inflection points.

Key Decisions for Investors

• Long LLY equity (size 2-4% portfolio) — horizon 6-18 months to capture share gains from product-line expansion and payer wins. Use a protective 12% trailing stop and scale into weakness; aim for 25-40% upside target tied to adoption milestones.
• LLY calendar call spread: buy 12-month 15% OTM calls and sell 3-month 15% OTM calls (debit spread) — plays asymmetric upside while monetizing short-term volatility; risk limited to premium (~0.8-1.5% of notional), potential 3-4x payoff if adoption accelerates.
• Pair trade — long LLY / short NVO (equal notional) over 9-12 months: expresses view that a successful oral launch will reallocate new-to-class patients to the company faster than incumbent share gains; hedge size to neutralize broad GLP-1 category moves and focus on share shift.
• Event-driven hedge: buy 6-9 month put protection on LLY sized 25-30% of long exposure ahead of major payer/regulatory announcements or quarterly results — cost of protection may be justified given tail-risk from adverse safety/payer rulings.